Steven Feldman to Cost-Benefit Analysis
This is a "connection" page, showing publications Steven Feldman has written about Cost-Benefit Analysis.
Connection Strength
3.093
-
Davis SA, Himmler S, Feldman SR. Cost-effectiveness analysis of using dermatologists versus pediatricians to treat mild to moderate acne. Dermatol Online J. 2017 May 15; 23(5).
Score: 0.547
-
Feldman SR, Zhao Y, Gilloteau I, Graham CN, Miles L, McBride D, Herrera V. Higher Psoriasis Skin Clearance Is Associated with Lower Annual Indirect Costs in the United States: A Post Hoc Analysis from the CLEAR Study. J Manag Care Spec Pharm. 2018 Jul; 24(7):617-622.
Score: 0.148
-
Vale SM, Hill D, Feldman SR. Pharmacoeconomic Considerations in Treating Actinic Keratosis: An Update. Pharmacoeconomics. 2017 02; 35(2):177-190.
Score: 0.134
-
Taieb A, Stein Gold L, Feldman SR, Dansk V, Bertranou E. Cost-Effectiveness of Ivermectin 1% Cream in Adults with Papulopustular Rosacea in the United States. J Manag Care Spec Pharm. 2016 Jun; 22(6):654-65.
Score: 0.127
-
James SM, Hill DE, Feldman SR. Costs of Common Psoriasis Medications, 2010-2014. J Drugs Dermatol. 2016 Mar; 15(3):305-8.
Score: 0.126
-
Rouse NC, Farhangian ME, Wehausen B, Feldman SR. The cost-effectiveness of ustekinumab for moderate-to-severe psoriasis. Expert Rev Pharmacoecon Outcomes Res. 2015; 15(6):877-84.
Score: 0.123
-
Feldman SR, Burudpakdee C, Gala S, Nanavaty M, Mallya UG. The economic burden of psoriasis: a systematic literature review. Expert Rev Pharmacoecon Outcomes Res. 2014 Oct; 14(5):685-705.
Score: 0.112
-
Mauskopf J, Samuel M, McBride D, Mallya UG, Feldman SR. Treatment sequencing after failure of the first biologic in cost-effectiveness models of psoriasis: a systematic review of published models and clinical practice guidelines. Pharmacoeconomics. 2014 Apr; 32(4):395-409.
Score: 0.110
-
Ahn CS, Gustafson CJ, Sandoval LF, Davis SA, Feldman SR. Cost effectiveness of biologic therapies for plaque psoriasis. Am J Clin Dermatol. 2013 Aug; 14(4):315-26.
Score: 0.105
-
Yentzer BA, Gustafson CJ, Feldman SR. Explicit and implicit copayments for phototherapy: examining the cost of commuting. Dermatol Online J. 2013 Jun 15; 19(6):18563.
Score: 0.104
-
Alikhan A, Daly M, Wu J, Balkrishnan R, Feldman SR. Cost-effectiveness of a hydroquinone/tretinoin/fluocinolone acetonide cream combination in treating melasma in the United States. J Dermatolog Treat. 2010 Sep; 21(5):276-81.
Score: 0.086
-
Anis AH, Bansback N, Sizto S, Gupta SR, Willian MK, Feldman SR. Economic evaluation of biologic therapies for the treatment of moderate to severe psoriasis in the United States. J Dermatolog Treat. 2011 Apr; 22(2):65-74.
Score: 0.084
-
Balkrishnan R, Bhosle MJ, Fleischer AB, Feldman SR. Prior authorization for topical psoriasis treatments: is it cost-beneficial for managed care? J Dermatolog Treat. 2010 May; 21(3):178-84.
Score: 0.084
-
Balkrishnan R, Bhosle MJ, Camacho F, Fleischer AB, Feldman SR. Prescribing patterns for topical retinoids: analyses of 15 years of data from the national ambulatory medical care survey. J Dermatolog Treat. 2010 May; 21(3):193-200.
Score: 0.084
-
Nolan BV, Yentzer BA, Feldman SR. A review of home phototherapy for psoriasis. Dermatol Online J. 2010 Feb 15; 16(2):1.
Score: 0.083
-
Thomas K, Yelverton CB, Yentzer BA, Balkrishnan R, Fleischer AB, Feldman SR. The cost-effectiveness of rosacea treatments. J Dermatolog Treat. 2009; 20(2):72-5.
Score: 0.077
-
Neidecker MV, Davis-Ajami ML, Balkrishnan R, Feldman SR. Pharmacoeconomic considerations in treating actinic keratosis. Pharmacoeconomics. 2009; 27(6):451-64.
Score: 0.077
-
Feldman S, Pearce DJ, Williford PM. Surgical decision making for basal-cell carcinoma of the face. Lancet Oncol. 2008 Dec; 9(12):1119-20.
Score: 0.076
-
Nelson AA, Pearce DJ, Fleischer AB, Balkrishnan R, Feldman SR. Cost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment period. J Am Acad Dermatol. 2008 Jan; 58(1):125-35.
Score: 0.071
-
Steele T, Pawaskar M, Balkrishnan R, Fleischer A, Feldman SR. Does cost-effectiveness play a role in clinical trials? Dermatol Ther. 2007 Mar-Apr; 20(2):110-9.
Score: 0.067
-
Miller DW, Feldman SR. Cost-effectiveness of moderate-to-severe psoriasis treatment. Expert Opin Pharmacother. 2006 Feb; 7(2):157-67.
Score: 0.063
-
Yelverton CB, Kulkarni AS, Balkrishnan R, Feldman SR. Home ultraviolet B phototherapy: a cost-effective option for severe psoriasis. Manag Care Interface. 2006 Jan; 19(1):33-6, 39.
Score: 0.062
-
Pearce DJ, Nelson AA, Fleischer AB, Balkrishnan R, Feldman SR. The cost-effectiveness and cost of treatment failures associated with systemic psoriasis therapies. J Dermatolog Treat. 2006; 17(1):29-37.
Score: 0.062
-
Nelson AA, Pearce DJ, Fleischer AB, Balkrishnan R, Feldman SR. New treatments for psoriasis: which biologic is best? J Dermatolog Treat. 2006; 17(2):96-107.
Score: 0.062
-
Simpson GL, Yelverton CB, Rittenberg S, Feldman SR. Do utilization management controls for phototherapy increase the prescription of biologics? J Dermatolog Treat. 2006; 17(6):359-61.
Score: 0.062
-
Stein KR, Pearce DJ, Feldman SR. The impact of biologics on the quality of life of psoriasis patients and the economics of psoriasis care. Semin Cutan Med Surg. 2005 Mar; 24(1):52-7.
Score: 0.059
-
Pearce DJ, Thomas CG, Fleischer AB, Feldman SR. The cost of psoriasis therapies: considerations for therapy selection. Dermatol Nurs. 2004 Oct; 16(5):421-8, 432.
Score: 0.057
-
Parks L, Balkrishnan R, Hamel-GariƩpy L, Feldman SR. The importance of skin disease as assessed by "willingness-to-pay". J Cutan Med Surg. 2003 Sep-Oct; 7(5):369-71.
Score: 0.053
-
Wu JJ, Feldman SR, Rastogi S, Menges B, Lingohr-Smith M, Lin J. Comparison of the cost-effectiveness of biologic drugs used for moderate-to-severe psoriasis treatment in the United States. J Dermatolog Treat. 2018 Dec; 29(8):769-774.
Score: 0.037
-
Armstrong AW, Feldman SR, Korman NJ, Meng X, Guana A, Nyirady J, Herrera V, Zhao Y. Assessing the overall benefit of a medication: cumulative benefit of secukinumab over time in patients with moderate-to-severe plaque psoriasis. J Dermatolog Treat. 2017 May; 28(3):200-205.
Score: 0.032
-
Lin HC, Lucas PT, Feldman SR, Balkrishnan R. Medication use and associated health care outcomes and costs for patients with psoriasis in the United States. J Dermatolog Treat. 2012 Jun; 23(3):196-202.
Score: 0.022
-
Inglese MJ, Fleischer AB, Feldman SR, Balkrishnan R. The pharmacoeconomics of acne treatment: where are we heading? J Dermatolog Treat. 2008; 19(1):27-37.
Score: 0.018
-
McCall BP, Horwitz IB, Feldman SR, Balkrishnan R. Incidence rates, costs, severity, and work-related factors of occupational dermatitis: a workers' compensation analysis of Oregon, 1990-1997. Arch Dermatol. 2005 Jun; 141(6):713-8.
Score: 0.015
-
Marchetti A, Feldman SR, Kimball AB, Anderson RR, Miller LH, Martin J, An P. Treatments for mild-to-moderate recalcitrant plaque psoriasis: expected clinical and economic outcomes for first-line and second-line care. Dermatol Online J. 2005 Mar 01; 11(1):1.
Score: 0.015
-
Duque MI, Jordan JR, Fleischer AB, Williford PM, Feldman SR, Teuschler H, Chen GJ. Frequency of seborrheic keratosis biopsies in the United States: a benchmark of skin lesion care quality and cost effectiveness. Dermatol Surg. 2003 Aug; 29(8):796-801; discussion 801.
Score: 0.013
-
Dehkharghani S, Bible J, Chen JG, Feldman SR, Fleischer AB. The economic burden of skin disease in the United States. J Am Acad Dermatol. 2003 Apr; 48(4):592-9.
Score: 0.013
-
Housman TS, Feldman SR, Williford PM, Fleischer AB, Goldman ND, Acostamadiedo JM, Chen GJ. Skin cancer is among the most costly of all cancers to treat for the Medicare population. J Am Acad Dermatol. 2003 Mar; 48(3):425-9.
Score: 0.013
-
Smith ES, Fleischer AB, Feldman SR, Williford PM. Characteristics of office-based physician visits for cutaneous fungal infections. an analysis of 1990 to 1994 National Ambulatory Medical Care Survey Data. Cutis. 2002 Mar; 69(3):191-8, 201-2.
Score: 0.012